Overview
Registration
Agenda
Faculty
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc.; Adaptive Biotechnologies Corporation; and Amgen, Inc.

Taking Action With Minimal Residual Disease: Technique, Role, and Utilization of MRD to Improve Outcomes in Patients With Hematologic Malignancies

Taking Action With Minimal Residual Disease: Technique, Role, and Utilization of MRD to Improve Outcomes in Patients With Hematologic Malignancies


Friday, December 4, 2020

Live, Interactive Virtual Webcast!

11:00 AM – 1:15 PM PST

Overview

Advances in treatment options for hematologic malignancies have improved outcomes for many patients over the past decade. However, treatment is not always curative, and many patients still relapse as a result of malignant cells that persist after treatment that have historically gone undetected. The small proportion of residual malignant cells in patients during or following treatment is known as measurable (or minimal) residual disease (MRD). MRD may be a function of poor tumor cytoreduction or rapid regrowth of tumor clones with high proliferation potential. The incorporation of MRD measurement into patient care provides an opportunity to reduce relapse or progression by ensuring optimal treatment strategies are used to reduce or eliminate residual malignant cells.

This engaging program will include a combination of brief didactic presentations followed by expert panel discussion to help place advances in MRD assessment into the context of patient care. In addition to examining available and emerging strategies for MRD monitoring throughout the care continuum in hematologic malignancies, the expert panel also will discuss updates in treatment strategies for acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL). In addition, this program will feature a question-and-answer session, allowing interaction with the experts to further understanding of the applications of MRD testing.

Benefits of Attending

  • Learn the latest techniques and applications of MRD measurement.
  • Hear from experts how they are incorporating MRD to improve patient care.
  • Gain insight into the latest data regarding treatment options for patients with ALL, CLL, MM, and DLBCL.
  • Interact with the expert panel to get answers to your questions about the role of MRD monitoring in hematologic malignancies.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc.; Adaptive Biotechnologies Corporation; and Amgen, Inc.

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in MRD monitoring for patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in MRD monitoring for patients with hematologic malignancies are also invited to attend.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify the advantages and challenges associated with available techniques for the monitoring of MRD.
  • Assess the role of MRD monitoring in the management of hematologic malignancies based on best evidence and consensus guidelines.
  • Apply emerging data regarding the role of MRD assessment to clinical scenarios for patients with hematologic malignancies.
  • Evaluate the current and future role of MRD status as an efficacy measurement in clinical trials.

Program Chair

Andre H. Goy, MD
Andre H. Goy, MD
Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer - John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology- Hackensack Meridian School of Medicine at Seton Hall University
Professor of Medicine – Georgetown University
Hackensack, NJ

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By